Authors

ctDNA Is Improving Oncology Care and Should Be Part of the Standard of Care

Many oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.

McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid Cancer

During a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.

Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Experts Compare Available Regimens for a Patient With Sarcomatoid Features

During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.

SHP2 Inhibitors Undergo Exploration in Combinations

Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.

ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial Cancer

An olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.

Six Tips for Identifying Go-Getters for Your Practice

The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.

Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance Therapy

Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.

Sequential Delivery Bests Concurrent Administration of CAR T-Cell Therapy in Pediatric CNS Tumors

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Addressing Clinical Trial Challenges in the Outpatient Setting

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup Analysis

Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.

Medicaid Cuts Create Barriers for Oncologists and Patients With Cancer

Gwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times.

An Update on Current and Emergent Therapies for Essential Thrombocytosis

The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.

Bemarituzumab Triplet OS Benefit Attenuates in FGFR2b+ Gastric/GEJ Cancer

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.

Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.

Tiragolumab Triplet Misses PFS in Untreated HCC

Can Just-in-Time Clinical Trials Reduce Disparities in Participation?

Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.

Beyond the Genome: Exploring New Frontiers in NSCLC Management

Biomarker testing in non–small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.

JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.